CLINICAL AND EXPERIMENTAL HYPERTENSION

metrics 2024

Pioneering research for a healthier tomorrow.

Introduction

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

Metrics 2024

SCIMAGO Journal Rank0.45
Journal Impact Factor1.50
Journal Impact Factor (5 years)1.60
H-Index55
Journal IF Without Self1.50
Eigen Factor0.00
Normal Eigen Factor0.34
Influence0.36
Immediacy Index0.90
Cited Half Life6.90
Citing Half Life5.70
JCI0.49
Total Documents2089
WOS Total Citations2156
SCIMAGO Total Citations9266
SCIMAGO SELF Citations381
Scopus Journal Rank0.45
Cites / Document (2 Years)1.57
Cites / Document (3 Years)1.64
Cites / Document (4 Years)1.65

Metrics History

Rank 2024

Scopus

Internal Medicine in Medicine
Rank #78/167
Percentile 53.29
Quartile Q2
Physiology in Biochemistry, Genetics and Molecular Biology
Rank #123/193
Percentile 36.27
Quartile Q3

IF (Web Of Science)

PERIPHERAL VASCULAR DISEASE
Rank 67/96
Percentile 30.70
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 265/354
Percentile 25.30
Quartile Q3

JCI (Web Of Science)

PERIPHERAL VASCULAR DISEASE
Rank 53/96
Percentile 44.79
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 243/354
Percentile 31.36
Quartile Q3

Quartile History

Similar Journals

Metabolic Syndrome and Related Disorders

Pioneering Research in Endocrinology and Metabolism
Publisher: MARY ANN LIEBERT, INCISSN: 1540-4196Frequency: 10 issues/year

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

BLOOD PRESSURE

Pioneering insights in cardiology and internal medicine.
Publisher: TAYLOR & FRANCIS LTDISSN: 0803-7051Frequency: 6 issues/year

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

Journal of Clinical Hypertension

Fostering Collaboration for Cardiovascular Excellence
Publisher: WILEYISSN: 1524-6175Frequency: 12 issues/year

Journal of Clinical Hypertension, published by WILEY, is a leading open-access journal focused on advancing the understanding and treatment of hypertension and related cardiovascular conditions. With an ISSN of 1524-6175 and an E-ISSN of 1751-7176, the journal provides a vital platform for researchers, healthcare professionals, and students alike to disseminate high-quality, peer-reviewed research. Since transitioning to open access in 2021, it has increased its reach and accessibility, ensuring critical information is available to a broader audience. The journal holds an impressive position in the Scopus ranks, nestled within the Q2 quartile across key disciplines including Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Internal Medicine, indicating a strong impact on the scientific community. With articles converging from 2001 to 2024, it not only highlights contemporary developments but also contributes to the ongoing dialogue in the field. Researchers are encouraged to submit their findings on hypertension, treatment methodologies, and epidemiology to further enhance the collective knowledge in this crucial area of health.

HYPERTENSION

Empowering professionals with cutting-edge findings.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0194-911XFrequency: 12 issues/year

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

EUROPEAN JOURNAL OF HEART FAILURE

Advancing heart failure research for a healthier tomorrow.
Publisher: WILEYISSN: 1388-9842Frequency: 12 issues/year

The European Journal of Heart Failure, published by Wiley, is a premier international journal dedicated to advancing the field of cardiology, specifically focusing on heart failure research and clinical practices. With an impressive impact factor and ranked in the top 1% of journals in Cardiology and Cardiovascular Medicine according to Scopus rankings (Rank #7/387, Percentile 98th), this journal serves as a vital resource for researchers, clinicians, and students alike. Spanning from 1999 to 2024, the journal has established itself as a cornerstone for innovative research, comprehensive reviews, and clinical insights, fostering a deeper understanding of heart failure mechanisms, management, and treatment strategies. Although not an open-access journal, the European Journal of Heart Failure remains committed to disseminating high-quality, peer-reviewed content that contributes significantly to the global cardiovascular community. Located in the United States at 111 River St, Hoboken, NJ 07030-5774, it continues to play an essential role in shaping the future of heart failure management.

International Journal of Chronic Obstructive Pulmonary Disease

Empowering Research for Better Lung Health
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2005Frequency: 1 issue/year

The International Journal of Chronic Obstructive Pulmonary Disease, published by DOVE MEDICAL PRESS LTD, serves as a premier platform for researchers and professionals involved in the study and management of COPD. Established in 2006 and transitioning to an Open Access model in 2009, this journal has quickly gained a reputable standing in various impactful categories, achieving Q1 rankings in Health Policy, Medicine (Miscellaneous), and Public Health, among others. With a focus on disseminating high-quality research, the journal is pivotal for addressing global public health challenges associated with chronic obstructive pulmonary disease. The journal's dedication to open access ensures that vital information reaches a broader audience, fostering advancements in research and clinical practice. By maintaining rigorous peer-review standards and a commitment to the advancement of understanding in COPD, the journal attracts significant contributions from scientists and practitioners worldwide, making it an invaluable resource for ongoing education and research development in this critical area.

Clinical Hypertension

Unlocking the future of hypertension science.
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

DIABETES OBESITY & METABOLISM

Bridging science and clinical practice in metabolic health.
Publisher: WILEYISSN: 1462-8902Frequency: 12 issues/year

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Clinica e Investigacion en Arteriosclerosis

Advancing cardiovascular knowledge for a healthier tomorrow.
Publisher: ELSEVIERISSN: 0214-9168Frequency: 6 issues/year

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Canadian Respiratory Journal

Innovating respiratory medicine with cutting-edge research.
Publisher: HINDAWI LTDISSN: 1198-2241Frequency: 1 issue/year

The Canadian Respiratory Journal is a prominent peer-reviewed publication dedicated to advancing knowledge in the field of pulmonary and respiratory medicine. Published by HINDAWI LTD and based in Egypt, this journal has been an Open Access platform since 1994, ensuring broad dissemination of vital research findings to a global audience. With an ISSN of 1198-2241 and an E-ISSN of 1916-7245, the journal plays a significant role in shaping respiratory health discussions, evidenced by its 2023 category rankings of Q2 in Medicine (miscellaneous) and Q3 in Pulmonary and Respiratory Medicine. The journal consistently publishes high-quality research, reviews, and clinical guidelines that resonate with practitioners, researchers, and students alike. It serves as an essential resource for those seeking to stay at the forefront of developments in respiratory health, reflecting its commitment to enhancing practice and informing policy while recognizing its place in this vital medical field.